Urgent Update: Rezpegaldesleukin Shows Breakthrough in Atopic Dermatitis

URGENT UPDATE: New data from the global phase 2b REZOLVE-AD study confirms that rezpegaldesleukin, a novel biologic for treating moderate-to-severe atopic dermatitis, significantly improves patient outcomes. The results, announced just hours ago by Nektar Therapeutics, reveal promising effects after a 36-week blinded maintenance period involving 393 participants across various countries.

The study, which began in October 2023, highlighted that patients receiving rezpegaldesleukin showed substantial improvements in key efficacy measures, including the Eczema Area and Severity Index (EASI). Notably, complete skin clearance (EASI-100) increased from 4% to 22% among those receiving monthly doses by week 52. This breakthrough impacts an estimated 30 million individuals in the US suffering from this chronic condition.

Dr. Jonathan Silverberg, a leading dermatologist, stated, “These data show that rezpegaldesleukin is emerging as one of the most important mechanisms in development to treat atopic dermatitis.” The study’s findings underscore the potential for this drug to revolutionize treatment approaches, offering new hope for patients.

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for rezpegaldesleukin, paving the way for expedited development and review. Patients aged 12 years and older with atopic dermatitis are the primary focus for this innovative treatment.

During the 52-week study, patients were randomized to receive various doses of rezpegaldesleukin or placebo. Those achieving at least a 50% reduction in their EASI scores during the initial 16-week induction phase were re-randomized to continue treatment. This approach resulted in durable disease control across multiple efficacy measures, including the validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD).

Notably, treatment retention rates remained high, with participants experiencing new and sustained responses. The safety profile of rezpegaldesleukin remained consistent with previous data, with adverse events reported in 72% of treated individuals, primarily mild and injection-site reactions.

Dr. David Rosmarin, chair of dermatology at Indiana University, emphasized, “These data highlight that rezpegaldesleukin offers a completely novel therapeutic modality for the potential treatment of atopic dermatitis.”

As this treatment progresses through clinical evaluation, the medical community and patients alike are watching closely. The implications for millions suffering from atopic dermatitis could be transformative, marking a critical advancement in dermatologic therapies.

Stay tuned for more updates as this story develops, and see how rezpegaldesleukin could change the landscape for treating atopic dermatitis.